BCP-01

N/A

Report date: 2025/01/26 16:36:07

Base Information

Drug NameBCP-01

Drug Alias Nameautologous blood-derived stem cell therapy (Hemostemix)BCP-01

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Osteogenic potential stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Peripheral blood stem cell therapy

Mechanisms of ActionBone synthesis stimulants

TargetsUpdating

Therapy Area/IndicationsFractures, BoneWounds and Injuries

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHemostemix Inc

China Registration ClassN/A

Develop Information

Active CompaniesHemostemix Inc

Inactive CompaniesN/A

Active IndicationsFractures, Bone

Inactive IndicationsWounds and Injuries

Other Information

ATC CodeN/A